HSV-TKHerpes Simplex Virus Thymidine Kinase Gene
References in periodicals archive ?
The clinical trials have confirmed that the HSV-TK gene therapy was superior to conventional treatments in the primary endpoints, especially in survival rates.
Takara Bio and MolMed have signed a licensing agreement whereby Takara Bio can exclusively commercialize MolMed's HSV-TK gene therapy in Asia and MolMed retains nonexclusive licenses for Takara's RetroNectin technology in Europe and the US.
expects the techniques to draw a total of about 45,000 latent patients, with 20,000 for treatment with HSV-TK gene, another 20,000 for HSV-TK-MAGE3 genes and 5,000 for AIDS.